ArticleEClinicalMedicine2025
Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esophageal neuroendocrine carcinoma: molecular insights, diagnostic advances, and emerging treatment strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) usually present with metastatic disease and have a poor prognosis. No standard therapies have been established beyond the first-line platinum-based chemotherapy. This study aims to evaluate the efficacy and safety of nab-paclitaxel plus bevacizumab in patients with previously treated advanced EP-NEC. Methods: This multicenter, single-arm, phase 2 trial was conducted from January 2021 to March 2024 to evaluate the efficacy and safety of nab-paclitaxel plus bevacizumab in patients with advanced EP-NEC who progressed after prior standard-of-care treatments. Patients were assigned to receive nab-paclitaxel of 150 mg/m Findings: A total of 79 patients were enrolled, with 40 patients receiving ≥2 lines of therapy. After a median follow-up of 22.4 (Interquartile Range [IQR] 14.7-42.9) months, the median OS was 12.8 (95% CI, 8.6-17.4) months. The median PFS was 5.3 (95% CI, 4.2-6.6) months. Among 76 patients with assessable best response, the ORR was 55% (42/76, 95% CI 43-67%), and DCR was 87% (66/76, 95% CI 77-94). The median DoR was 5.7 (95% CI, 3.3-7.2) months. Patients with gastric NEC had a numerically higher ORR compared with those with NEC from other sites, but statistical significance was not achieved (26/39, [67%] vs. 16/37, [43%]; Interpretation: Patients with metastatic EP-NEC achieved a high response rate and encouraging survival with tolerable toxicity. The combination regimen has the potential to become a valuable treatment option, if further controlled studies confirm its efficacy for patients who have exhausted standard therapies. Funding: This study was partially supported by Qilu Pharmaceutical Co., Ltd. This work is supported by the Beijing Municipal Science & Technology Commission (No. Z231100007223002).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.